Adma Biologics (ADMA) Return on Capital Employed (2011 - 2025)
Adma Biologics (ADMA) posted Return on Capital Employed of 36.33% for Q4 2025, up 10.3% on a QoQ basis from 32.94% in Q3 2025, and up 15.0% year-over-year from 31.59% in Q4 2024.
Adma Biologics (ADMA) Return on Capital Employed (2011 - 2025) Analysis & Trends
Adma Biologics' Return on Capital Employed history runs 13 years deep, the most recent figure standing at 36.33% for Q4 2025.
- Quarterly Return on Capital Employed rose 15.0% year-over-year to 36.33% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 36.33% (up 15.0% YoY) and the FY2025 annual result came in at 39.32%, down 1.0% from the prior year.
- Return on Capital Employed was 36.33% for Q4 2025 at Adma Biologics, up from 32.94% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 36.33% in Q4 2025 and bottomed at 31.58% in Q1 2021.
- A 5-year average of 2.67% and a median of 2.56% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed soared 3349 bps — and 2025, when it tumbled 99 bps.
- Adma Biologics' Return on Capital Employed stood at 25.71% in 2021, then soared by 46 bps to 13.8% in 2022, then surged by 154 bps to 7.48% in 2023, then surged by 384 bps to 36.18% in 2024, then grew by 0 bps to 36.33% in 2025.
- Business Quant data shows ADMA's Return on Capital Employed at 36.33% in Q4 2025, 32.94% in Q3 2025, and 33.87% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Adma Biologics | 1.99 Bn | 1.91 Bn | 88.82 Mn | 36.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36.33% |
| Sep 30, 2025 | 32.94% |
| Jun 30, 2025 | 33.87% |
| Mar 31, 2025 | 34.08% |
| Dec 31, 2024 | 36.18% |
| Sep 30, 2024 | 33.93% |
| Jun 30, 2024 | 26.28% |
| Mar 31, 2024 | 15.43% |
| Dec 31, 2023 | 7.48% |
| Sep 30, 2023 | 0.44% |
| Jun 30, 2023 | -5.55% |
| Mar 31, 2023 | -8.24% |
| Dec 31, 2022 | -13.80% |
| Sep 30, 2022 | -18.28% |
| Jun 30, 2022 | -18.81% |
| Mar 31, 2022 | -22.27% |
| Dec 31, 2021 | -25.71% |
| Sep 30, 2021 | -30.68% |
| Jun 30, 2021 | -28.59% |
| Mar 31, 2021 | -31.58% |